MedTrace Logo

A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

NCT06503679 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2025-01-24

No results posted yet for this study

Summary

The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

LY4100511 (DC-853) Dose 1

Administered orally

DRUG

LY4100511 (DC-853) Dose 2

Administered orally

DRUG

LY4100511 (DC-853) Dose 3

Administered orally

DRUG

Midazolam

Administered orally

DRUG

Repaglinide

Administered orally

DRUG

Digoxin

Administered orally

DRUG

Rosuvastatin

Administered orally

Sponsors & Collaborators

  • DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

    lead INDUSTRY

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-16
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06503679 on ClinicalTrials.gov